A Phase 1/2a, Open-label, multicenter, first-in-human trial in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations.
Evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy
A study investigating the safety, tolerability, PK, PD, and preliminary efficacy.
A Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CLN-418 (HBM7008), and to determine the maximum tolerated dose and/or recommended Phase 2 study dose in patients with advanced solid tumors.
A Phase 1 monotherapy dose escalation/expansion study.